Ocular Hypertension News and Research

RSS

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

Sunridge International, announced today that China's State Food and Drug Administration, (SFDA), had approved the firm's Pneumatic Trabeculoplasty (PNT) treatment in China.

3 Mar 2010

Sunridge International extends distribution contract with Beijing Vision World Trading

Sunridge International announced today that they have extended the exclusive distribution agreement with Beijing Vision World Trading Co., Ltd. for an additional 4 years.

6 Feb 2010

Alcon signs definitive agreement to acquire Optonol

Alcon announced today that it has entered into a definitive agreement to acquire Optonol, Ltd., a medical device company that develops, manufactures and markets novel miniature surgical implants used to lower intraocular pressure (IOP) in patients with glaucoma.

14 Dec 2009

Allergan reports operating results for the third quarter of 2009

Allergan, Inc. today announced operating results for the quarter ended September 30, 2009. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on November 30, 2009 to stockholders of record on November 9, 2009.

29 Oct 2009

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

A first-time finding of intraocular pressure increases in patients with no personal or family history of glaucoma following anti-VEGF treatment for wet age-related macular degeneration (AMD), and a report on a simple, low-cost method that could revolutionize vision screening and treatment in developing countries, are highlights of today's Scientific Program of the 2009 Joint Meeting of the American Academy of Ophthalmology (AAO) and the Pan-American Association of Ophthalmology (PAAO).

27 Oct 2009

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive results from a Phase 2a study of its Rho-kinase (ROCK) inhibitor, AR-12286. The study evaluated the safety, tolerability and efficacy of three different doses of AR-12286 in 88 patients with primary open angle glaucoma or ocular hypertension.

22 Oct 2009

NicOx reports financial results for the first nine months of 2009

NicOx S.A. today reported financial results for the nine months ended September 30, 2009.

22 Oct 2009

Rio Grande Dermatology offers eyelash drugs for $99

Many women desire to have thicker and longer eyelashes. Previously this could only be accomplished with the use of fake lashes. However, due to the discovery of a desirable side effect of a glaucoma drug, Latisse was born. Rio Grande Dermatology, providers of comprehensive dermatology treatments for the Albuquerque metropolitan area, is proud to offer this highly anticipated "eyelash drug" for an introductory price of $99 dollars.

24 Sep 2009

SAFLUTAN launched in United Kingdom and Spain

Merck Sharp & Dohme (MSD) has launched SAFLUTAN (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today.

3 Sep 2009

Merck's SAFLUTAN launched in the UK and Spain

Merck & Co., Inc. has launched SAFLUTAN® (tafluprost) in the United Kingdom and Spain, and additional launches in other countries are expected over the next several months, pending regulatory approvals, the Company said today. SAFLUTAN is a preservative free, synthetic analogue of the prostaglandin F2α for the reduction of elevated intraocular pressure (IOP) in appropriate patients with primary open-angle glaucoma and ocular hypertension.

3 Sep 2009

Subject enrollment in patients with retinitis pigmentosa for Phase 2 clinical study completed by R-Tech Ueno

We are pleased to announce that subject enrollment for the phase 2 clinical study of 0.15% UF-021 (generic name; isopropyl unoprostone; active ingredient of Rescula(R) eye-drops) in patients with retinitis pigmentosa has been completed.

25 Aug 2009

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

20 Aug 2009

Aton Pharma acquires Timoptic product line from Merck & Co

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the Timoptic product line from Merck & Co., Inc. Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

25 Feb 2009

NicOx updates on PF-03187207 and research collaboration with Pfizer

NicOx S.A. has announced the results of a dose-ranging phase 2 study conducted with PF‑03187207 in Japanese patients with glaucoma by its partner Pfizer Inc. PF-03187207 is a nitric oxide-donating prostaglandin analog. The study was designed to compare the safety and efficacy of several doses of PF-03187207 to Xalatan (latanoprost) and enrolled 112 Japanese patients with primary open-angle glaucoma or ocular hypertension.

25 Aug 2008

Glaucoma associated with increased risk of cardiovascular death in black patients

In a population of African origin, persons with diagnosed and treated glaucoma appeared to have an increased risk of death from cardiovascular causes, according to a study by Suh-Yuh Wu, and colleagues in the Departments of Preventive Medicine and Ophthalmology at Stony Brook University, the University of the West Indies, and the Cleveland Clinic Foundation.

12 Mar 2008

Glaucoma associated with increased risk of cardiovascular death in black patients

Black patients with diagnosed and treated glaucoma and those with high pressure in their eyes appear to have an increased risk of death from cardiovascular causes, according to a report in the March issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

11 Mar 2008

Danube Pharmaceuticals starts trial of DNB-001 in patients with ocular hypertension

Danube Pharmaceuticals, Inc. has announced the initiation of a multi-center, randomized, double-blind, placebo controlled Phase II study with DNB-001 in 60 patients with ocular hypertension (elevated intraocular pressure).

18 May 2007

Treating glaucoma early significantly reduces economic health burden

Treatments that delay the progression of glaucoma may significantly reduce the economic health burden on people with the disease and on the U.S. health system, according to a new study by researchers at Duke University Eye Center and elsewhere. Their findings appear in the January 9, 2006, issue of Archives of Ophthalmology.

9 Jan 2006

New glaucoma risk calculator

High eye pressure is the leading risk factor for glaucoma, and is the only modifiable one. If glaucoma is untreated, vision loss may continue, leading to blindness in some individuals.

17 Oct 2005

New glaucoma risk assessment principles help physicians decide who needs treatment

A new approach for assessing glaucoma risk factors could be the first step in helping ophthalmologists determine the risk of progression from ocular hypertension to glaucoma and blindness, according to an article published today in the September issue of the American Journal of Ophthalmology.

14 Sep 2004

Ocular Hypertension News and Research

China's SFDA approves Sunridge International's PNT treatment for glaucoma and ocular hypertension

Sunridge International extends distribution contract with Beijing Vision World Trading

Alcon signs definitive agreement to acquire Optonol

Allergan reports operating results for the third quarter of 2009

Some patients with AMD develop elevated pressure within the eye following anti-VEGF medications: Study

Positive results from Aerie Pharmaceuticals’ Phase 2a study of its Rho-kinase inhibitor

NicOx reports financial results for the first nine months of 2009

Rio Grande Dermatology offers eyelash drugs for $99

SAFLUTAN launched in United Kingdom and Spain

Merck's SAFLUTAN launched in the UK and Spain

Subject enrollment in patients with retinitis pigmentosa for Phase 2 clinical study completed by R-Tech Ueno

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma acquires Timoptic product line from Merck & Co

NicOx updates on PF-03187207 and research collaboration with Pfizer

Glaucoma associated with increased risk of cardiovascular death in black patients

Glaucoma associated with increased risk of cardiovascular death in black patients

Danube Pharmaceuticals starts trial of DNB-001 in patients with ocular hypertension

Treating glaucoma early significantly reduces economic health burden

New glaucoma risk calculator

New glaucoma risk assessment principles help physicians decide who needs treatment

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News